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Summary
We examined how HLA types A1-B8-DR3 and B27
were related to progression of clinical disease and
rate of loss of CD4 lymphocytes in the Edinburgh
City Hospital cohort of HIV-positive patients, mainly
injection drug users. Patients (n = 692) were pro-
spectively followed from 1985 through March 1994.
Accurately estimated seroconversion times were
determined retrospectively for a subgroup of 313
(45%). Of 262 patients (39%) who were fully or
partially HLA typed, 155 (50%) had known serocon-
versions. Of 34 patients typed positive for A1-B8-
DR3, 29 progressed to CDC stage IV, 22 to AIDS
and 20 died. Twelve patients were typed positive
for B27; six of these progressed to CDC stage IV,
one to AIDS and none died. In a proportional
hazards analysis of the 313 patients with known
seroconversions, A1-B8-DR3 was significantly asso-
ciated with covariate-adjusted relative risks of 3.7
(95% Cl 1.9-7.2), 3.1 (1.6-6.0) and 1.9 (1.1-3.2)
for progression from seroconversion to death, AIDS
and CDC stage IV, respectively. Events for B27 were
too rare to include B27 in analyses to death and
AIDS, but B27 was significantly associated with
slower progression to CDC stage IV (0.3, Cl
0.1 -0.9). Random effects growth curve models were
used to estimate individual rates of loss of square
root CD4 count and loss of CD4 percentage, for
603 and 617 patients, respectively. A1-B8-DR3 was
associated with rapid loss of both markers (p=0.02
and p = 0.01, respectively); B27 was associated with
slow loss of both markers (p=0.04 and p< 0.005).
Introduction
Several studies have reported associations between
HIV disease progression and HLA antigens. Steel
et a/.1 investigated 32 Edinburgh haemophilia
patients exposed to a single batch of blood factor
contaminated with HIV, of whom 18 became HIV-
antibody-positive. They found that the antigen com-
bination A1-B8-DR3 (usually identified as a haplo-
type) was weakly associated with an increased risk
of seroconversion (relative risk 2.9) while, in those
who seroconverted, it was strongly associated with
the development of HIV-related symptoms; of 11
patients who developed symptoms, eight possessed
the haplotype, whilst none of seven patients
remaining symptom-free possessed the haplotype
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(relative risk 28). Graphical evidence that A1-B8-DR3
patients experienced faster CD4 loss was also noted.
Kaslow et al.2 provided further confirmation of this
finding in a study of 108 seropositive homosexual
men, composed of a group of 49 who showed rapid
decline in CD4 counts over a two-year period and a
group of 59 who showed little or no decline. Rapid
decliners were patients with CD4 count and CD4
percentage slopes in the fastest 15% of the Multicenter
AIDS Cohort Study (MACS) whilst slow decliners had
slopes in the slowest 35%. The groups were matched
for study centre, ethnic group and initial CD4 count,
and A1-B8-DR3 was significantly more common in
the rapid progressors (odds ratio 3.8).
Kaplan et al. found the A1-B8-DR3 and B8-DR3
combinations to be significantly associated with
progression from presentation to AIDS in 180 seropo-
sitive Europeans3 (relative risks 7.6 and 10.6 from Cox
model). They also found these combinations to be
significantly associated with rates of six-month CD4
lymphocyte loss greater than 20% (RRs 2.7 and 2.2).
We have followed up this work by investigating
the influence of HLA type A1-B8-DR3 on progression
and rate of loss of CD4 in a large cohort of HIV-
infected patients where, for a large subset of the
cohort, a narrow interval estimate of the date of
seroconversion was available. We also investigated
possible associations with B27, because of its known
association with other diseases (ankylosing spondyl-
itis, Reiter's syndrome) and, more importantly,
because of recent work suggesting there are similarit-
ies between HLA class 2 DR B1 chain and the
carboxyterminus of the HIV-1 envelope gp120, when
presented as peptides by B27, which leads to the
hypothesis that B27 might be associated with slower
progression.4 An earlier analysis of the Edinburgh
data5 gave credibility to this hypothesis.
Data are from the Edinburgh City Hospital
Cohort,6"10 a prospectively followed cohort which
commenced recruitment in 1985, and which is com-
posed of HIV-positive patients who visited the
Infectious Diseases Unit of the City Hospital from
1985 onwards; the modal risk behaviour in the cohort
is injection drug use. Because of a hepatitis B study
among Edinburgh injection drug users (IDUs) in the
early 1980s, a large amount of stored sera is available
for Edinburgh IDUs which has made it possible to
establish retrospectively a sub-cohort of patients with
well-determined lengths of infection, generally
acquired in 1983-85 and mostly through drug use.
Methods
Patients
At 24 March 1994, the Edinburgh City Hospital
cohort included 692 patients, of whom 262 (39%)
had been HLA typed. Of these 692, 313 (45%) had
narrow interval estimates of seroconversion, and we
refer to this subgroup as the seroconversion cohort;
155 members (50%) of the seroconversion cohort
were HLA-typed (Table 1).
At 24 March 1994, the cohort contained 206
women (30%) and 470 (68%) injection drug users
(IDUs). There had been 221 AIDS cases and 212
deaths (145 AIDS, 26 overdoses, 24 medical non-
AIDS, 16 other); 430 patients (62%) had been treated
with zidovudine (AZT).
The seroconversion cohort contained 102 women
(32%) and was dominated by IDUs (281, 90%);
mean age at seroconversion was 23.6 (90% age
range 17.5-34.7) and the majority of patients (85%)
were estimated to have seroconverted in 1983-85.
There had been 84 AIDS cases and 82 deaths (46
AIDS, 13 overdoses, 16 medical non-AIDS, six other);
206 people (66%) had been treated with AZT.
Seroconversion determination
For the seroconversion cohort, seroconversion times
were determined by either (i) observation of sero-
conversion illness, (ii) the midpoint of positive and
negative HIV tests not more than two years apart,
(iii) the midpoint of January 1983 and a positive HIV
test not more than two years after January 1983, the
assumed epidemic start date in Edinburgh IDUs, or
(iv) detailed knowledge of injection behaviour.
Numbers of determinations by the four methods
were 13, 99, 166 and 35. Interval estimates by
methods (ii) and (iii) were considered to be subject
to a year's error at most.
January 1983 was taken as the estimated epidemic
start, as it was the earliest known date for any drug
user in Edinburgh to have seroconverted for HIV.11
In proportional hazards analyses of clinical progres-
sion from estimated seroconversion to clinical endpo-
ints of CDC stage IV, AIDS and death, patients with
seroconversions determined from the imputed epi-
demic start date (iii) had slower progression than
patients with seroconversions determined by the
other methods; there were no differences between
the other methods. When the estimated epidemic
start date was temporarily moved forward to July
1983, this effect disappeared. This suggests both that
January 1983 is a conservative last negative date in
method (iii), and that estimates of seroconversion are
accurate enough to reveal such small differences.
Analyses of covariates in this paper are controlled
for seroconversion determination method.
HLA methodology
The HLA typing exercise was initiated in the sickest
patients so that the information could be obtained
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Table 1 Summary statistics for whole cohort and seroconversion cohort
Cohort: Whole Seroconversion
Number of patients
Number HLA typed
Infected through IDU
Homosexually infected
Heterosexually infected
Infected through blood products
Unclear risk activity
Women
IDUs who are women (as % of IDUs)
Heterosexual ly infected women
Mean age at enrolment/serocon.* (SD)
CDC stage IV cases
AIDS cases
Deaths:
AIDS deaths (as % of all deaths)
Death for medical reasons but not AIDS
Drugs overdoses
Unknown causes
Zidovudine (AZT) recipients
Mean clinic visits (SD)
692
262
470
107
103
8
4
206
137
67
29.4
413
221
212
145
24
26
16
430
19.4
39%
68%
15%
15%
1%
0%
30%
29%
65%
7.5
60%
32%
31%
68%
11%
12%
8%
62%
16.1
313
155
281
10
19
3
0
102
88
13
23.6
185
84
82
46
16
13
6
206
22.9
50%
90%
3%
6%
1%
0%
32%
31%
68%
5.2
59%
27%
26%
56%
20%
16%
7%
66%
15.9
* Enrolment in case of whole cohort; seroconversion for seroconversion cohort
whilst they were still alive, since at the time the
study was undertaken it was a much more difficult
task to determine HLA types retrospectively from
DNA strands in stored sera. Further typing of addi-
tional patients then concentrated on gaining more
complete information on those with narrow sero-
conversion intervals. HLA typing was by a standard
two-stage complement-dependent microlymphocyto-
toxicity technique.12
Analysis of clinical progression
For the seroconversion cohort, proportional hazards
models13 from seroconversion to CDC stage IV, AIDS
and death were used to explore HLA associations
with progression rate. Additional covariates in the
models controlled for gender, exposure category, age
at seroconversion and method of seroconversion
determination; that is, the additional covariates
allowed us to estimate HLA effects net of the possible
influences of other factors. A covariate for AZT use
was not included, but AZT use was widespread in
the study group and was not found (in a further
unreported analysis) to have an influence on estim-
ated HLA effects.
To test the effect of HLA antigens, three indicator
variables were constructed for patients who were:
(i) positive for the antigen or antigen combination in
question; (ii) untyped; (iii) typed in insufficient detail
to judge whether they had, or had not, the antigen
or antigen combination in question. Thus the baseline
group was taken to be the patients who were
definitely negative for the antigen in question.
Analysis of immunological progression
To see whether HLA types were associated with
faster or slower immunological progression, hierarch-
ical regression models14"16 were used to derive
shrinkage estimates of individual rates of decay of
square root CD4 count and CD4 percentage, for
individuals with at least two determinations of the
marker in question. The square root transformation
was chosen for CD4 counts to stabilize variances
and induce normality. Shrinkage estimates were used
since, on average over the study group, they give
considerably more accuracy than do simple least
squares estimates of decay slopes.15 Shrinkage estim-
ates are essentially very similar to the estimates
derived from multilevel modelling17 which have been
used to estimate root CD4 slopes in reference 18.
Associations between estimated slopes of decay
and HLA antigens were sought using multiple linear
regression. HLA antigens were coded using indicator
variables as in the proportional hazards models
(although seven were now required to analyse A1-
B8-DR3 and B27 simultaneously) and additional
covariates were again included to control for gender,
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exposure category, age and (for the seroconversion
group) method of seroconversion determination. The
analysis was performed both for the whole cohort
and for the seroconversion cohort, and sensitivity to
the number of marker measurements used was
checked and found to be modest. AZT effects were
again not considered; in earlier work we found the
impact of treatment to be a small and transitory
increase in CD4 level without strong evidence of an
accompanying alteration of slope.14
Simple plots and linear regressions of square root
CD4 count against time from seroconversion were
used to show graphically the longitudinal behaviour
of CD4 count, as well as the timing of any clinical
diagnoses, for the nine patients from the seroconver-
sion cohort who were B27-positive; it may also be
of interest to other researchers to know the full
phenotypes of these patients, as far as these have
been determined.
Results
Table 2 shows the numbers typed and the proportions
typed positive for A1-B8-DR3 and B27. Of the 262
typed patients in the cohort, 34 had the antigens A1,
B8 and DR3 in their phenotype (which is most likely
to mean that they received the combination as a
complete haplotype) and 13 were typed in insuffi-
Table 2 Numbers typed positive for A1-B8-DR3 and B27
cient detail to tell whether they were A1-B8-DR3 or
not. Of the 155 typed patients in the seroconversion
group, 21 were A1-B8-DR3 and five were not fully
typed. Thus, in both cases, about 14% of the fully
typed individuals were A1-B8-DR3, which was a
slightly lower proportion than expected. Steel ef al.
have suggested an expected frequency of occurrence
of 25% in Scotland and Jazwinska and Kilpatrick19
reported a frequency of 20% in parents of 132 babies
born at an Edinburgh maternity unit (see final column
of table).
Of 226 patients in the cohort fully typed for B27,
12 had the antigen B27. In the seroconversion
cohort, 9/134 fully typed patients were B27. The
observed frequencies of B27 in fully typed individuals
(5% and 7%) were thus in line with an expected
frequency of occurrence of 8%.19
Analysis of clinical progression
In the proportional hazards analysis of progression
from seroconversion to clinical endpoints for the 313
members of the seroconversion cohort, A1-B8-DR3
emerged as a significant predictor of faster progres-
sion (Table 3). A1-B8-DR3 was associated with
adjusted relative risks of 3.7 (95% Cl 1.9-7.2) of
dying, 3.1 (1.6-6.0) of developing AIDS and 1.9
(1.1-3.2) of reaching CDC stage IV. Very similar
results were obtained in an analysis restricted to the
Group
Whole cohort
(n = 692, 262 typed)
Seroconversion
(n = 313, 155 typed)
Table 3 Results of a
Group
Seroconversion
(n = 313)
A1-B8-DR3
Not A1-B8-DR3
Undetermined
Untyped
IDU subgroup
(n = 260)
A1-B8-DR3
Not A1-B8-DR3
Undetermined
Untyped
HLA
combination
A1-B8-DR3
B27
A1-B8-DR3
B27
Positive
34
12
21
9
(%)
14%
5%
14%
7%
Negative
215
214
129
125
Incomplete typing Expected frequency19
13
36
5
21
proportional hazards analysis of the effect of A1-B8-DR3
Number
21
129
5
158
20
113
4
123
Dead RR
82
13
28
1
40
74
13
27
1
31
3.7
1
1.0
1.2
3.8
1
1.0
1.2
Cl
1.9-7.2
Baseline
0.1-7.9
0.7-2.0
1.9-7.5
Baseline
0.1-7.7
0.7-2.0
AIDS
84
13
27
1
33
75
13
36
1
23
RR
3.1
1
1.0
0.7
3.1
1
0.9
0.7
20%
8%
20%
8%
I on progression to clinical endpoints
Cl
1.6-6.0
Baseline
0.1-7.0
0.4-1.3
1.6-6.0
Baseline
0.1-7.0
0.4-1.2
CDC IV
185
17
89
4
75
170
17
82
4
59
RR
1.9
1
3.4
0.7
2.0
1
3.7
0.7
Cl
1.1-3.2
Baseline
1.2-9.5
0.5-1.0
1.2-3.4
Baseline
1.3-10.4
0.5-0.9
RR, relative risk adjusted for gender, age, risk group and method of seroconversion determination.
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260 members of the seroconversion cohort who
were infected through IDU in the initial years of the
epidemic 1983-1985 (Table 3).
The analysis also showed that possible biases
induced by the nature of the typing of the cohort
were not severe. The untyped patients had a signific-
antly lowered risk of progression to CDC stage IV
(RR 0.7, Cl 0.5-1.0), perhaps explained by the fact
that typing began with the most seriously ill patients,
but this effect was not evident in the analyses to
AIDS and death.
In the case of B27 the proportional hazards form
of analysis was less appropriate since none of the
nine patients in the seroconversion cohort who were
typed positive for this antigen developed AIDS or
died. However three reached CDC stage IV and a
significantly reduced progression rate to this endpoint
(RR 0.3, Cl 0.1-0.9) could be demonstrated.
Analysis of immunological progression
Slope estimates for decay of root CD4 count could
be derived for 603 members of the cohort (who
possessed at least two CD4 count measurements), of
whom 290 were also in the seroconversion cohort.
The mean number of counts per patient was 14.9
(SD 10.4) and 491 patients (81%) had five or more
counts. Estimates for rate of decay of CD4 percentage
could be derived for 617 patients, of whom 295
were also in the seroconversion cohort. The mean
number of measurements was 15.5 (SD 10.7) and
507 patients (82%) had more than five meas-
urements.
In the group of 603 patients with estimated root
CD4 slopes there were 33 patients with A1-B8-DR3.
Their mean slope per annum was —2.1 and the
standard deviation of the slopes was 1.3. These
estimates were based on a mean of 19 counts per
individual (SD 9.4). In contrast, the 12 patients typed
positive for B27 had a mean slope of —1.00 (SD
1.2) based on a mean of 25 counts (SD 9.3). The
mean slope over the whole group of 603 was — 1.6
(SD 1.0).
In linear regression analyses of root CD4 slope
against HLA type (Table 4), done for both the whole
cohort and the seroconversion cohort, and controlled
for other covariates, there were significant associ-
ations between A1-B8-DR3 and fast immunological
progression, and between B27 and slow immunolo-
gical progression. Relative to the baseline group who
were negative for both HLA types, the presence of
A1-B8-DR3 was associated with differences in rate
of decay of - 0 . 4 5 (SE 0.19, p = 0.02) for the whole
cohort and - 0 . 7 5 (SE 0.21, p<0.001) for the
seroconversion cohort; the presence of B27 was
associated with differences in rate of decay of 0.62
(SE 0.30, p = 0.04) and 0.72 (SE 0.31, p = 0.02)
respectively.
Out of 617 patients assigned rates of CD4 percent-
age loss, the 33 patients with A1-B8-DR3 had a
mean slope of —2.3 (SD 1.9), based on an average
of 20 counts (SD 9.2). The 12 B27 patients had a
mean slope of —0.5 (SD 1.5), based on an average
of 27 counts (SD 8.9). The mean rate over the whole
group of 617 was - 1 . 7 (SD 1.4).
In linear regression analyses of CD4 percentage
slope against HLA type (Table 5), done as for CD4
count, there were again significant associations
between A1-B8-DR3 and fast immunological progres-
sion and between B27 and slow immunological
progression. Relative to the baseline group who were
negative for both HLA types, the presence of A1-B8-
DR3 was associated with differences in rate of decay
of - 0 . 6 4 (SE 0.25, p = 0.01) for the whole cohort
and - 0 . 7 0 (SE 0.24, p<0.005) for the seroconver-
sion cohort; the presence of B27 was associated with
differences in rate of decay of 1.18 (SE 0.40,
p < 0.005) and 1.15 (SE 0.35, p<0.005) respectively.
In all regression analyses, the results changed very
Table 4 Association of A1-B8-DR3 and B27 with rate of loss of square root CD4 count
Group
A1-B8-DR3
Perhaps A1-B8-DR3
B27
Perhaps B27
Perhaps either
Untyped
Neither A1-B8-DR3/B27
Whole
n
603
33
5
12
27
8
344
173
Cohort
Coeff.
-0.45
-0.13
0.62
0.24
-0.05
0.06
Baseline
SE
0.19
0.46
0.30
0.21
0.37
0.10
P
0.02
0.78
0.04
0.24
0.89
0.53
Seroconversion Cohort
n
290
21
2
9
18
3
135
Coeff.
-0.75
-0 .10
0.72
0.33
0.53
0.05
Baseline
SE
0.21
0.64
0.31
0.23
0.52
0.12
P
<0.01
0.87
0.02
0.15
0.31
0.66
Multiple linear regression analyses controlled for sex, exposure category, age and method of seroconversion determination
(for the seroconversion cohort).
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Table 5 Association of
Group
A1-B8-DR3
Perhaps A1-B8-DR3
B27
Perhaps B27
Perhaps either
Untyped
Neither A1-B8-DR3/B27
A1-B8-DR3 and
Whole
n
617
33
5
12
28
8
358
173
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B27 with rate of
cohort
Coeff.
-0.64
-0.68
1.18
0.52
0.19
0.10
Baseline
loss of
SE
0.25
0.60
0.40
0.27
0.48
0.13
CD4 percentage
P
0.01
0.26
<0.01
0.06
0.70
0.44
Seroconversion cohort
n
295
21
2
9
18
3
135
Coeff.
-0 .70
-1.01
1.15
0.52
0.25
0.04
Baseline
SE
0.24
0.72
0.35
0.26
0.60
0.13
P
<0.01
0.16
<0.01
0.05
0.68
0.77
Multiple linear regression analyses controlled for sex, exposure category, age and method of seroconversion determination
(for the seroconversion cohort).
little when the selection criteria were changed so
that only patients with five or more marker deter-
minations were eligible. A1-B8-DR3 remained asso-
ciated with faster progression and B27 with slower.
When the 603 patients with estimated root CD4
slopes were ranked by these slopes and divided into
quarters representing very fast, moderately fast, mod-
erately slow and very slow progressors (Table 6)
13/33 A1-B8-DR3 carriers (39%) were in the fastest
quarter and 13 in the intermediate half; however,
seven (21%) were found in the slowest quarter,
showing that A1-B8-DR3 does not lead exclusively
to poor outcomes. However, among the 13 patients
in the fastest quarter there were some exceptionally
fast progressors: seven (21 % of 33) were in the fastest
10% of the group, and five (15% of 33) were in the
fastest 5% of the group.
Seven out of 12 B27 patients (58%) were in the
slowest quarter, three were in the intermediate half
and two (17%) were in the fastest quarter. Plots of
the nine B27 patients from the seroconversion cohort
mostly showed slow CD4 loss or stable counts (see
Figure 1), with the exception of patient 209901 who
was one of the two patients in the fastest quarter.
Simple linear regression lines indicated that no
patient had fallen below a CD4 count threshold of
100/mm3 within 10 years and there were no AIDS
diagnoses or deaths. Three of these patients had
been diagnosed with ARC, as had the three other
B27 patients who were not members of the seroconv-
ersion cohort; one of these also reached AIDS
although none had died.
Discussion
Our results support previous studies which have
shown the haplotype A1-B8-DR3 to be associated
with fast progression of HIV disease.1"3 We have
conducted a much larger study of the influence of
HLA antigens in the setting of a prospectively fol-
lowed cohort where accurately estimated seroconver-
sion times are available for a sizeable subgroup. Our
data gave strong evidence of faster average clinical
and immunological progression in patients carrying
this haplotype and, given this rapidity of progression,
they raise the issue of whether HLA type should be
considered in the context of future prospective clin-
ical trials.
The City Hospital cohort from which these data
come is dominated by a young group of needle-
sharing IDUs who were mostly infected in
1983-1985.6"10 Some 470 (68%) cohort members
and 281 (90%) seroconversion cohort members are
believed to have been infected through IDU, 260 of
Table 6 Rates of CD4 loss in 603 patients ranked into quarters and crosstabulated with HLA
Group
A1-B8-DR3
Perhaps A1-B8-DR3
B27
Perhaps B27
Perhaps either
Neither
Untyped
Fastest quarter
(n=151)
13
2
2
6
3
67
58
Intermediate
(n = 151)
8
0
0
5
0
25
113
Intermediate
(n=151)
5
3
3
8
3
31
98
Slowest quarter
(n = 150)
7
0
7
9
2
59
66
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Patient No. 54762 A1.31 B44.27 DR4,5(11) Patient No. 83289 A11.28 B27.60 DR2.4 Patient No. 201671 A2 B44.27 DR1,4
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. . . . .
Years Irom seroconverslon
Patient No. 201675 A25.31 B27.51 DR4
Years Irom seroconverslon
Patient No. 209901 A1,33 B27.38 DR5
Years Irom seroconverslon
Patient No. 212281 A2,3 B8.27 DR2
Years Irom seroconverslon
Patient No. 212801 A?B27DR1,7
Years Irom seroconverslon
Patient No. 220051 A23.26 B49.27 DR?
Years Irom seroconverslon
Patient No. 220687 A2.11 B7.27 DR2
Years Irom seroconverslon Years Irom seroconverslon Years Irom seroconverslon
Figure 1. CD4 decline on square-root scale for nine B27 patients with well-estimated seroconversions; dotted lines are
linear regression estimates of the patterns of root CD4 decay; vertical lines denote CDC stage IV diagnoses (marked ARC);
full HLA types are given.
the latter in 1983-85. To maximize numbers we
considered all patients in this paper, regardless of
risk group. In Table 2, in an analysis of clinical
progression restricted to the 260 IDUs infected in
1983-85, we checked that very similar A1-B8-DR3
results were obtained to those derived from the
whole seroconversion cohort.
We were able to look carefully at HLA effects on
clinical progression because of our accurate know-
ledge of seroconversion times for a subset (45%) of
the cohort. In seroconversions estimated from interval
data (85% of cases) the maximum possible error in
the estimate was one year; in the remaining cases
estimated through observation of seroconversion ill-
ness and detailed knowledge of drug-using behavi-
our, the estimates were also likely to be accurate. It
was possible to make accurate interval seroconver-
sion estimates for so many people because of the
availability of stored sera.
Because of our knowledge of seroconversions, we
could use survival analysis methods based on the
proportional hazards model, with survival measured
from this natural origin. This is the most accurate
way of estimating the influence of HLA antigens, or
any other covariates, on clinical progression. Studies
which measure progression times from other origins
such as first known occasion of HIV-positivity
(so-called prevalent cohort studies such as the study
of Kaplan et a/.3 are prone to a series of biases in
estimation of covariate effects, especially onset con-
founding.20 Studies which use case-control methods
(such as those of Steel et al. and Kaslow ef a/.1'2
cannot estimate the relative progression risks associ-
ated with HLA type.
The second strength of our study was the availabil-
ity of a large amount of longitudinal CD4 count and
CD4 percentage data which allowed the study of
HLA associations with immunological progression.
CD4 monitoring is performed regularly in the
Edinburgh cohort (every three months for most
patients, more frequently for the sicker patients and
patients on AZT) and at 24 March 1994, the mean
number of counts per patient was 13.1 over the
whole cohort; 491 patients (71%) had five or more
counts. With this volume of data, the characterization
of decay rates in the cohort becomes possible but,
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because CD4 count and CD4 percentage are volatile
markers and because the amount and quality of the
information on decay rate vary from individual to
individual, the use of hierarchical-model-based
shrinkage methods is preferable to the application of
simple maximum likelihood (least squares) estima-
tion.15 Our slope estimates are thus likely to be more
accurate than those used in earlier A1-B8-DR3
studies,1"3 and the number of patients for whom we
have slope estimates is much greater.
We chose to use all possible available information
on rate by including patients with as few as two
CD4 counts in our analysis. This had negligible
bearing on our study of HLA associations with rate
(Tables 3 and 4) since (a) estimates for patients with
few counts are generally set very close to the mean
rate and are not influential, and (b) patients with
types A1-B8-DR3 and B27 generally had more
markers measurements than average. However, we
also verified empirically that very similar results were
obtained when the analysis was restricted to patients
with at least five counts.
The prevalence (14%) of A1-B8-DR3 in the fully
typed individuals in this study was slightly lower
than expected (20%). It is possible that a larger
proportion of those who died rapidly before typing
began carried the haplotype, although this hypothesis
is now difficult to test. It seems less likely that
additional members of the cohort died rapidly with
B27, since this HLA antigen is rare and the observed
frequencies matched the expected frequencies.
On the other hand, for the IDU members of the
study group, it could also be argued that the expected
population frequencies are not appropriate compar-
isons, since the study group is not a completely
random sample from the general population and
there were many needle-sharing networks which
included several family members. Because of the
need to preserve confidentiality, it is difficult to
initiate an active study of familial links in the cohort
but, in an informal enumeration by City Hospital
clinicians, it was found that among 164 IDU patients
with at least ten CD4 determinations it was possible
to count 17 patients in eight families with first-order
relationships (sibling, parent-child) to other cohort
members, and this was merely a lower bound on
the total number of blood relationships in this group
where there are also second-order relationships
(cousin, uncle/aunt).
The underlying biological basis for the association
of A1-B8-DR3 with rapid progression of HIV-related
disease and CD4 loss remains obscure. The haplo-
type A1-B8-DR3 is well known to be associated with
a wide range of autoimmune disorders and indi-
viduals bearing this haplotype could be considered
to be immunologically 'hyper-responsive' (see also
discussion of Steel et aV This suggests that autoim-
munity may be responsible for the progressive
immunodeficiency rather than any direct cytopathic
effect of HIV on CD4 lymphocytes, but the mechan-
ism at the molecular level by which this occurs is
still unclear.
The second major association we observed was
between B27 and slow progression. One of 12
patients typed positive for this antigen reached AIDS,
but no patients died, and it seemed that these patients
were experiencing slow immunological decay. There
has been recent interest in the phenomenon of long-
term survival in HIV patients and in the explanation
for the differences between such patients and rapid
progressors.21'22 One suggestion put forward is that
differences are due to a less virulent strain of HIV-122
but our data, as well as those of others, raise the
possibility that it could also be due to decreased
susceptibility in the host. In two recent reports the
number of long-term survivors (10-15 years) infec-
tion varied from 5 to 15% of cohorts.23'24 One of
these cohorts reported on HLA associations, and
noted greater frequencies of A32, B4 and C2 in the
long-term survivors.23 Our report of an association
with B27 adds further to the suggestion that there
may be an immunological as well as, or instead of,
a virological explanation of the phenomenon of long-
term survival.
In addition, there appears to be an underlying
molecular basis for our observation of slow progres-
sion in patients with B27. The experiments of Ohno4
have shown that the nonapeptide derived from gp120
has virtually 'optimal' binding characteristics for HLA
B27 and is therefore likely to be 'tolerogenic' in that
it resembles the preferred self peptides presented to
T cells on this molecule. It could therefore be argued
that this association of B27 with a slow immuno-
logical progression supports the proposal that the
immunodeficiency that develops following HIV infec-
tion is due to an autoimmune mechanism.
Habeshaw has proposed that the gp120 carboxy-
terminal region mimics HLA DR beta chain alleles
for class 1 presentation. In the case of DR B1 alleles
presented by HLA B27, the binding motif expressed
by the DR B1 chain is well mimicked by the
carboxyterminal gp120 sequence. For the DR B3
alleles, the mimicry is poor and so the HIV-1
carboxyterminal sequence would represent an allo-
epitope of DR B3 when expressed upon the B27
molecule. The presence of an allogeneic MHC
component (or peptide mimic thereof) 'breaks toler-
ance' of self MHC-derived peptides.25"27
In summary, we have confirmed that A1-B8-DR3
is associated with a rapid development of immuno-
deficiency after HIV infection. However we have
also observed that HLA B27 is associated with a
slow development of HIV immunodeficiency, a find-
ing that could be expected if autoimmune mechan-
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isms played a major role in the development of
immunodeficiency, since studies at the molecular
level have demonstrated that a nonapeptide derived
from the HIV envelope protein is tolerogenic when
presented to T cells on the HLA B27 molecule.
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